Compare APEI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APEI | STTK |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 875.2M | 792.9M |
| IPO Year | 2007 | 2020 |
| Metric | APEI | STTK |
|---|---|---|
| Price | $43.28 | $6.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $62.83 | $14.67 |
| AVG Volume (30 Days) | 194.0K | ★ 864.5K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.27 | 53.02 |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $198,174,000.00 | $1,000,000.00 |
| Revenue This Year | $6.88 | N/A |
| Revenue Next Year | $5.93 | N/A |
| P/E Ratio | $28.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.20 | $1.70 |
| 52 Week High | $61.59 | $8.33 |
| Indicator | APEI | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 60.14 |
| Support Level | $42.72 | $6.75 |
| Resistance Level | $45.25 | $7.75 |
| Average True Range (ATR) | 1.74 | 0.39 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 46.62 | 90.10 |
American Public Education Inc provides online and campus based postsecondary education including various undergraduate and graduate degree programs. The fields of study include business administration, health science, technology, criminal justice, education, liberal arts, national security, military studies, intelligence, and homeland security. There are three reporting segments: the American Public University segment which is the key revenue generator, provides online postsecondary education as a distance-learning, graduate-level institution for military officers seeking a degree in military studies; the Rasmussen University Segment and the Hondros College of Nursing segment. The revenue is generated from net course registrations and enrollment, tuition rate, net tuition, and other fees.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.